CHO Cell Line Technology Indian Lupin Partners with NeuClone for CHO Cell Line Technology

Editor: Dominik Stephan

– Lupin has signed a strategic licensing agreement with Sydney-based private specialty life science company Neu-Clone for their cell line technology.

Related Companies

(Picture: Lupin)
(Picture: Lupin)

Mumbai/India – Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian Chinese Hamster Ovary (CHO) cell line, which will express a specific recombinant protein of interest in oncology to its partner.

“The multi-billion dollar opportunity with blockbuster Biologics going off patent in the next five to eight years is something that Lupin is pursuing aggressively. This exclusive licensing arrangement with NeuClone is a part of that strategy and would enable us to capitalize on cutting edge technology to address the Biologicals market. This agreement and such similar agreements, coupled with our own pipeline will go a long way in helping us address the impending opportunity and develop a substantial differentiated biological pipeline,” says Dr. Cyrus Karkaria, President, Lupin and Head of the Lupin Biological Research Program.

NeuClone CEO, Dr Noelle Sunstrom says, “We are enthusiastic about further developing the relationship with Lupin.”